Express Mail No.: EV 335 856 882 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Cheng et al.

Serial No.: To be assigned
(Continuation of Application No.:
08/436,960, filed June 5, 1995)

Group Art Unit: To be Assigned

Filed: September 4, 2003

Examiner: To Be Assigned

For: Method of Treating or Preventing Hepatitis B Virus

Attorney Docket No.: 6523-038-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A18, B01-B28 and C01-C58,** which are listed on the accompanying form PTO-1449 entitled "List of References Cited By Applicant." This application is a continuation of, *inter alia,* application Serial No. 08/463,960, filed June 5, 1995 (the "'960 application"), presently pending. A copy of references **A01-A17, B01-B28, and C01-C55** can be found in the '960 application file and, pursuant to 37 C.F.R. § 1.98(d)(1), is not enclosed. Applicants would provide the Examiner with a copy of references **A01-A17, B01-B28, and C01-C55,** however, upon request. A copy of references **A18, C56, C57 and C58** is submitted herewith. Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants with to inform the Examiner that the '960 application had been involved in: (a) Interference No. 104,396, in which priority of invention was awarded against Cheng, a co-inventor of the presently claimed subject matter; and (b) Interference No. 104,523, in which priority of invention was awarded against Furman, the party adverse to Cheng in that interference.

The presently claimed subject matter is patentably distinct from that of Interference No. 104,396 and Interference No. 104,523.

Applicants respectfully request that the Examiner review all the references identified on the attached form PTO-1449 and make them of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits (37 C.F.R. § 1.97(b)), Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Pennie & Edmonds Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date September 4, 2003

Matthew E. Langer 36,343

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 6523-038	APPLICATION NO TBA
	APPLICANT Cheng et al.	
	FILING DATE September 4, 2003	GROUP TBA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,000,137	12/28/76	Dvonch et al.			
	A02	4,336,381	6/22/82	Nagata et al.			
	A03	4,861,759	8/29/89	Mitsuya et al.			
	A04	4,879,277	11/7/89	Mitsuya et al.			
	A05	4,916,122	4/10/90	Chu et al.			
	A06	4,963,533	10/16/90	de Clercq et al.			
	A07	5,047,407	9/10/91	Belleau et al.			
	A08	5,059,690	10/22/91	Zahler et al.			
	A09	5,071,983	12/10/91	Koszalka et al.			
	A10	5,179,104	1/12/93	Chu et al.			
	A11	5,185,437	2/9/93	Koszalka et al.			
	A12	5,204,466	4/20/93	Liotta et al.			
	A13	5,210,085	5/11/93	Liotta et al.			
	A14	5,248,776	9/28/93	Chu et al.			
	A15	5,532,246	7/02/96	Belleau et al.			
	A16	5,539,116	7/23/96	Liotta et al.			
	A17	5,587,480	12/24/96	Belleau et al.			
	A18	6,350,753	2/26/02	Belleau et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	B01	EP 206 497 B1	7/20/94	EP				
	B02	EP 302 760 B1	7/29/92	EP				
	B03	EP 337 713 A2	10/18/89	EPO				
	B04	EP 375 329 A2	6/27/90	EPO				
	B05	EP 382 526 A2	8/16/90	EPO				
	B06	EP 433 898 A	6/26/91	EPO				

	B07	EP 494 119 A1	7/8/92	EPO				
	B08	EP 515 144 A1	5/19/92	EPO				
	B09	EP 515 156 A1	11/25/92	EP				
	B10	EP 515 157 A1	11/25/92	EPO				
	B11	EP 526 253 A1	2/3/93	EPO				
	B12	GB 9009861.7	11/14/91	GB				
	B13	GB 9100039.8	7/23/92	GB				
	B14	GB 9109506.7	11/12/92	GB				
	B15	GB 9109913.5	7/23/92	GB				
	B16	GB 9111902.4	12/10/92	GB				
	B17	WO 90/12023	10/18/90	PCT				
	B18	WO 91/11186	8/8/91	PCT				
	B19	WO 91/11186	8/8/91	PCT				
	B20	WO 91/17159	11/14/91	PCT				
	B21	WO 92/10496	6/25/92	PCT				
	B22	WO 92/10497	6/25/92	PCT				
	B23	WO 92/11852	7/23/92	PCT				
	B24	WO 92/14743	9/3/92	PCT				
	B25	WO 92/15308	9/17/92	PCT				
	B26	WO 92/18517	10/29/92	PCT				
	B27	WO 92/19246	11/12/92	PCT				
	B28	WO 92/21676	12/10/92	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
	C01	Balzarini et al., 1986, "Potent and selective ant-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine", Biochem Biophys Res Comm 140(2):735-742.
	C02	Belleau et al., 1989, "Design and activity of a novel class of nucleoside analogs effective against HIV-1", 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989.
	C03	Carter et al., 1990, "Activities of (-)-carbovir and 3'azido-3'deoxythymidine against human immunodeficiency virus in vitro", Antimicrob Agents Chemother 34(6):1297-1300.
	C04	Chang et al., 1987, "Production of hepatitis B virus *in vitro* by transient expression of cloned HBV DNA in a hepatoma cell line", EMBO J 6(3):675-680.
	C05	Chang et al., 1992, "Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication", J Biol Chem 267:13938-13942.

	C06	Chen and Cheng, 1989, "Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immuodeficiency virus compound 2,'3'-dideoxycytidine", J Biol Chem 264(20):11934-11937.
	C07	chromatograph alleging to show that BCH-189 was separated into its individual enantiomers using a chiral triacetylcellulose column (see Third Supplemental Information Disclosure Statement under 37 C.F.R. § 1.56)
	C08	Chu et al., 1988, "An efficient total synthesis of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZDDU, CS-87) from D-mannitol", Tetrahedron Letters 29(42):5349-5352.
	C09	Chu et al., 1988, "Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells", Biochem Pharmacol 37(19):3543-3548.
	C10	Chu et al., 1989, "Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells", J Med Chem 32:612-617.
	C11	Cretton et al., 1991, "Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'deoxythymidine, a highly toxic catabolite for human bone marrow cells", Mol Pharmacol 39:258-266.
	C12	Cretton et al., 1991, "Pharmacokinetics of 3'-azido-3'deoxythymidine and its catabolites and interactions with probenecid in Rhesus monkeys", Antimicrob Agents Chemother 35(5):801-807.
	C13	Di Bisceglie et al., 1988, "Hepatocellular carcinoma", Ann Intern Med 108:390-401.
	C14	Doong et al., 1991, "Inhibition of the replication of hepatitis B virus *in vitro* by 2',3'-dideoxy-3'-thiacytidine and related analogues", Proc Natl Acad Sci 88:8495-8499.
	C15	E.L. Eliel, *Stereochemistry of Carbon Compounds* 31-86 (1962)
	C16	F.A. Farraye et al., "Preliminary Evidence that Azidothymidine does not Affect Hepatitis B Virus Infection in Acquired Immunodeficiency Syndrome (AIDS) Patients," *J. Med. Virol.* 29:266-67 (1989)
	C17	Furman et al., 1992, "The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the the (-) and (+) enantiomers of *cis*-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine", Antimicrob Agents Chemother 36(12):2686-2692.
	C18	Ganem and Varmus, "The molecular biology of the hepatitis B virus", Ann Rev Biochem 56:651-693.
	C19	H. Haritani et al., "Effect of 3'-Azido-3'-Deoxythymidine on Replication of Duck Hepatitus B Virus *In Vivo* and *In Vitro*," *J. Med. Virol.* 29:244-48 (1989)
	C20	H.E. Varmus, "A Growing Role for Reverse Transcription," *Nature* 299:204-205 (1982)
	C21	Jeong et al., 1993, "Asymmetric synthesis and biological evaluation of β-L-(2R,5S)- and α-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents", J Med Chem 36(2):181-195.
	C22	Kassianides et al., 1989, "Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine: A potential inhibitor of reverse transcriptase", Gastroenterology 97:1275-1280.
	C23	Krenitsky et al., 1983, "3'-amino-2',3'-dideoxyribonucleosides of some pyrimidines: Synthesis and biological activities", J Med Chem 26(6):891-895.
	C24	Lee et al., 1989, "In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus", Antimicrob Agents Chemother 33(3):336-339.

	C25	Lin et al., 1987, "Potent and selective *in vitro* activity of 3'-deoxythymidin-2'ene(3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus", Biochem Pharmacol 36(17):2713-2718.
	C26	M. Mahmoudian et al., "Enzymatic Production of Optically Pure (2'R-*cis*)-2'-deoxy-3'-thiacytidine (3TC, Lamivudine): A potent anti-HIV agent," *Enzyme Microb. Technol.* 15:749-55 (1993)
	C27	Matthes et al., 1990, "Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides", Antimicrob Agents Chemother 34(16):1986-1990.
	C28	Memorandum, 1988, "Progress in the control of viral hepatitis: Memorandum from a WHO meeting", Bull WHO 66(4)):443-455.
	C29	Miller and Robinson, 1986, "Common evolutionary origin of hepatitis B virus and retroviruses", Proc Natl Acad Sci 83:2531-2535.
	C30	Mitsuya et al., 1985, "3'-azido-3'deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus *in vitro*", Proc Natl Acad Sci 82:7096-7100.
	C31	Mitsuya et al., 1987, "Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV", in AIDS: Modern Concepts And Therapeutic Challenges, Broder (ed.), pp. 303-333.
	C32	Mitsuya et al., 1990, "Molecular targets for AIDS therapy", Science 249:1533-1544.
	C33	Norbeck et al., 1989, "(±)-Dioxolane-T: A new 2',3'-dideoxynucleoside prototype with *in vitro* activity against HIV", Tetrahedron Letters 30(46):6263-6266.
	C34	Okabe et al., 1988, "Synthesis of the dideoxynucleosides ddC and CNT from glutamic acid, ribolactone, and pyrimidine bases", J Org Chem 53(20):4780-4786.
	C35	Richman et al., 1987, "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex", New Engl J Med 317(4):192-197.
	C36	S.H. Wilen, *Tables of Resolving Agents and Optical Resolutions* 3-33 and 141-195 (1972)
	C37	Satsumabayashi et al., 1972, "The syntheses of 1,3-oxathiolan-5-one derivatives", Bull Chem Soc Japan 45:913-915.
	C38	Schinazi et al., 1992, "Activities of four optical isomers of 2',3'-dideoxy-3'thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes", Antimicrob Agents Chemother 36(3):672-676.
	C39	Schinazi et al., 1992, "Insights into HIV chemotherapy", AIDS Research and Human Retroviruses 8(6):963-990.
	C40	Schinazi et al., 1992, "Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in Rhesus monkeys", Antimicrob Agents Chemother 36(11):2432-2438.
	C41	Schinazi et al., 1992, "Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of *cis*-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine", Antimicrob Agents Chemother 36(11):2423-2431.
	C42	Schinazi et al., 1992, "Substrate specificity of *Escherichia coli* thymidine phosphorylase for pyrimidine nucleosides with-anti-human immunodeficiency virus activity", Biochem Pharmacol 44(2):199-204.
	C43	Sells et al., 1987, "Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA", Proc Natl Acad Sci 84:1005-1009.
	C44	Soudeyns et al., 1991, "Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog", Antimicrob Agents Chemother 35(7):1386-1390.

	C45	Sterzycki et al., 1990, "Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides", J Med Chem 33:2150-2157.
	C46	Storer et al., 1993, "The resolution and absolute stereochemistry of the enantiomers of *cis*-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (BCH189): Equipotent anti-HIV agents", Nucleosides and Nucleotides 12(2):225-236.
	C47	Sureau et al., 1986, "Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with a cloned circular HBV DNA", Cell 47:37-47.
	C48	Tsurimoto et al., 1987, "Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA", Proc Natl Acad Sci 84:444-448.
	C49	Volk (ed.), 1982, "Essentials of Medical Microbiology", pp. 609-618.
	C50	Vorbruggen et al., 1981, "Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts", Chem Ber 114:1234-1255.
	C51	W.H. Pirkle et al., "Chiral Stationary Phases for the Direct LC Separation of Enantiomers," *(journal title and date unavailable)*; pp 73-127
	C52	Wilson et al., 1990, "A general method for controlling glycosylation stereochemistry in the synthesis of 2'-deoxyribose nucleosides", Tetrahedron Letters 13:1815-1818.
	C53	Wilson et al., 1993, "The synthesis and anti-HIV activity of pyrimidine dioxolanyl nucleosides", Bioorg Med Chem Letters 3(2):169-174.
	C54	Yokota et al., 1990, "Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro", Antimicrob Agents Chemother 34(7):1326-1330.
	C55	Zhu et al., 1991, "Cellular metabolism of 3'-azido-2',3'-dideoxyuridine with formation of 5'-O-diphosphohexose derivatives by previously unrecognized metabolic pathways for deoxyuridine analogs", Mol Pharmacol 38:929-938.
	C56	Skalski et al., 1993, The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2',3'-dideoxy-3'-thiacytidine. J Biol Chem. 268(31):23234-8
	C57	De Clercq E. 1995, Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem. 38(14):2491-517. Review
	C58	Bastow et al. 1983, Susceptibility of phosphonoformic acid-resistant herpes simplex virus variants to arabinosylnucleosides and aphidicolin. Antimicrob Agents Chemother. 1983 Jun;23(6):914-7

EXAMINER	**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.